(By James K Griffin)
Diabetes mellitus, commonly known as diabetes, is a group of metabolic diseases in which blood sugar levels goes extremely high over a prolonged period. Antidiabetics are the medicines developed to stabilize and control blood glucose (sugar) levels amongst diabetes patient. Antidiabetic drugs are generally used to control diabetes. Insulin pramlintide (Amylin), GLP-1 receptor agonists such as byetta and victoza are the different types of antidiabetics drugs. The global antidiabetics market is driven by increasing prevalence of diabetes mellitus.
Increasing disposable income has been resulted into significant changes in lifestyle. This in turn has been resulted into increasing incidences of disorders such as obesity which may cause the diabetes. This is primarily triggered the demand for antidiabetics. Additionally, advancement in pharmaceutical sector helps to drive the antidiabetics market. However, high cost of insulin is expected to be a major restraint of antidiabetics market. The market size and forecasts in terms of revenue (USD million) for the period 2015 to 2020, considering 2014 as the base year, have been provided for this segment of the report. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2015 to 2020.
Access sample report visit at http://www.syndicatemarketresearch.com/request-for-sample.html?flag=S&repid=51861
The report provides a comprehensive view on the antidiabetics; we have included a detailed competitive scenario and product portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the antidiabetics market has also been included. The study encompasses a market attractiveness analysis, wherein product segments are benchmarked based on their market size, growth rate and general attractiveness.
The global antidiabetics market is segmented on the basis of product and region. The productsegments of the global antidiabetics market include insulin, rapid acting, long acting, premixed, premixed analog, short acting, intermediate acting, antidiabetics, alpha-glucosidase inhibitors, biguanides, sulphonylureas, glp-1 agonist, meglitinides, dpp-4 inhibitors, sglt – 2 and thiazolodinediones. Insulin dominated the overall market in terms of revenue.
Major regional segments analyzed in this study include North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, further bifurcation of region on the country level, which include U.S., Germany, UK, France, China, Japan and India. North America dominated antidiabetics market.
Some of the key players for global antidiabetics market include Boehringer Ingelheim GmbH, Astra Zeneca plc, Eli Lilly & Co., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, SanofiS.A., Johnson & Johnson, Mankind Pharma Ltd., and Teva Pharmaceutical Industries Ltd.
Inquiry for buying report visit at http://www.syndicatemarketresearch.com/market-analysis/antidiabetics-market.html